FDA Grants 510(k) Clearance to Roche's cobas eplex Respiratory Pathogen Panel
Roche (RHHBY) has received FDA 510(k) clearance for its cobas eplex respiratory pathogen panel 3. This diagnostic tool is capable of detecting up to 19 different viruses and bacteria, offering a comprehensive solution for respiratory infection identification. The system features five customizable panel configurations designed specifically for use with the cobas eplex platform. This development enhances Roche's diagnostic capabilities in the respiratory sector, providing healthcare providers with more versatile options for rapid pathogen detection.
Tickers: $RHHBY